Adamas Pharmaceuticals reported -9387000 in EBITDA for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Acadia Pharmaceuticals ACAD:US $ -42.78M 23.1M
Aerie Pharmaceuticals AERI:US $ -29.84M 2.88M
Aptinyx Inc APTX:US $ -19766000 5.89M
Flexion Therapeutics FLXN:US $ -16357000 6.26M
GlaxoSmithKline GSK:LN 2626M 584M
Glaxosmithkline GSK:US $ 2626M 584M
Gw Pharmaceuticals GWPH:US $ -17.18M 2.02M
Heron Therapeutics HRTX:US $ -59.74M 8.36M
Intra Cellular Therapies ITCI:US $ -69.02M 15.92M
Marinus Pharmaceuticals MRNS:US $ -23.4M 3.68M
Neurocrine Biosciences NBIX:US $ 70.4M 36.4M
Novartis NOVN:VX SF 4772M 423M
Omeros OMER:US $ -23661000 6.56M
Prothena PRTA:US 28.24M 60.04M
Revance Therapeutics RVNC:US $ -65.29M 0.48M
Teva Pharmaceutical TEVA:IT 1.14B 34M
Zogenix ZGNX:US $ -53.07M 3.63M